Do analysts prefer AADI or CELU?

Celularity has a consensus price target of $6.00, indicating a potential upside of 844.44%. Given Celularity's stronger consensus rating and higher possible upside, analysts clearly believe Celularity is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts prefer JATT or CELU?

Celularity has a consensus price target of $6.00, indicating a potential upside of 844.44%. Given Celularity's stronger consensus rating and higher probable upside, analysts clearly believe Celularity is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, JATT or CELU?

JATT Acquisition has higher earnings, but lower revenue than Celularity. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Celularity $26.55M 0.69 -$91.72M -$3.33 N/A

Do analysts rate RLYB or CELU?

Celularity has a consensus target price of $6.00, indicating a potential upside of 844.44%. Given Celularity's stronger consensus rating and higher possible upside, analysts clearly believe Celularity is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Celularity 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is RLYB or CELU more profitable?

Celularity has a net margin of -345.45% compared to Rallybio's net margin of -911.07%. Celularity's return on equity of 0.00% beat Rallybio's return on equity. Company Net Margins Return on Equity Return on Assets Rallybio -911.07% -55.79% -51.48% Celularity -345.45% N/A -77.94%

Celularity (CELU) Competitors

$0.64 -0.04 (-6.57%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$0.65 +0.02 (+2.63%)

As of 07/31/2026 07:34 PM Eastern

Compare

CELU vs. AADI, VRCA, HRTX, JATT, and RLYB

Should you buy Celularity stock or one of its competitors? MarketBeat compares Celularity with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Celularity include Aadi Bioscience (AADI), Verrica Pharmaceuticals (VRCA), Heron Therapeutics (HRTX), JATT Acquisition (JATT), and Rallybio (RLYB).

How does Celularity compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Aadi Bioscience has a net margin of -246.06% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Aadi Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Celularity	-345.45%	N/A	-77.94%

Aadi Bioscience has higher earnings, but lower revenue than Celularity. Aadi Bioscience is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	3.79	-$65.76M	-$2.35	N/A
Celularity	$26.55M	0.69	-$91.72M	-$3.33	N/A

Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Celularity has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

In the previous week, Aadi Bioscience's average media sentiment score of 0.00 equaled Celularity'saverage media sentiment score.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Celularity	Neutral

Celularity has a consensus price target of $6.00, indicating a potential upside of 844.44%. Given Celularity's stronger consensus rating and higher possible upside, analysts clearly believe Celularity is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 17.3% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Aadi Bioscience beats Celularity on 8 of the 14 factors compared between the two stocks.

How does Celularity compare to Verrica Pharmaceuticals?

Celularity (NASDAQ:CELU) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations.

Celularity presently has a consensus price target of $6.00, suggesting a potential upside of 844.44%. Verrica Pharmaceuticals has a consensus price target of $14.50, suggesting a potential upside of 177.78%. Given Celularity's higher possible upside, equities research analysts plainly believe Celularity is more favorable than Verrica Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Verrica Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Verrica Pharmaceuticals had 3 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Verrica Pharmaceuticals and 0 mentions for Celularity. Celularity's average media sentiment score of 0.00 beat Verrica Pharmaceuticals' score of -0.02 indicating that Celularity is being referred to more favorably in the media.

Company	Overall Sentiment
Celularity	Neutral
Verrica Pharmaceuticals	Neutral

Celularity has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Verrica Pharmaceuticals has a beta of 1.47, indicating that its share price is 47% more volatile than the broader market.

Verrica Pharmaceuticals has a net margin of -47.97% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Verrica Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Verrica Pharmaceuticals	-47.97%	-1,077.78%	-40.76%

19.0% of Celularity shares are held by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are held by institutional investors. 17.3% of Celularity shares are held by insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Verrica Pharmaceuticals has higher revenue and earnings than Celularity. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55M	0.69	-$91.72M	-$3.33	N/A
Verrica Pharmaceuticals	$35.58M	2.52	-$17.89M	-$1.03	N/A

Summary

Verrica Pharmaceuticals beats Celularity on 12 of the 16 factors compared between the two stocks.

How does Celularity compare to Heron Therapeutics?

Heron Therapeutics (NASDAQ:HRTX) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Heron Therapeutics has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Celularity has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

80.0% of Heron Therapeutics shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 6.1% of Heron Therapeutics shares are owned by company insiders. Comparatively, 17.3% of Celularity shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Heron Therapeutics has a net margin of -20.53% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heron Therapeutics	-20.53%	-7,747.30%	-8.94%
Celularity	-345.45%	N/A	-77.94%

Heron Therapeutics has higher revenue and earnings than Celularity. Heron Therapeutics is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heron Therapeutics	$154.90M	0.60	-$20.19M	-$0.18	N/A
Celularity	$26.55M	0.69	-$91.72M	-$3.33	N/A

In the previous week, Heron Therapeutics had 3 more articles in the media than Celularity. MarketBeat recorded 3 mentions for Heron Therapeutics and 0 mentions for Celularity. Heron Therapeutics' average media sentiment score of 1.24 beat Celularity's score of 0.00 indicating that Heron Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Heron Therapeutics	Positive
Celularity	Neutral

Heron Therapeutics presently has a consensus target price of $2.50, suggesting a potential upside of 406.07%. Celularity has a consensus target price of $6.00, suggesting a potential upside of 844.44%. Given Celularity's higher possible upside, analysts clearly believe Celularity is more favorable than Heron Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heron Therapeutics	2 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Heron Therapeutics beats Celularity on 10 of the 15 factors compared between the two stocks.

How does Celularity compare to JATT Acquisition?

JATT Acquisition (NYSE:JATT) and Celularity (NASDAQ:CELU) are related small-cap companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

JATT Acquisition has a net margin of 0.00% compared to Celularity's net margin of -345.45%. Celularity's return on equity of 0.00% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Celularity	-345.45%	N/A	-77.94%

Celularity has a consensus price target of $6.00, indicating a potential upside of 844.44%. Given Celularity's stronger consensus rating and higher probable upside, analysts clearly believe Celularity is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, JATT Acquisition had 1 more articles in the media than Celularity. MarketBeat recorded 1 mentions for JATT Acquisition and 0 mentions for Celularity. Celularity's average media sentiment score of 0.00 beat JATT Acquisition's score of -1.00 indicating that Celularity is being referred to more favorably in the news media.

Company	Overall Sentiment
JATT Acquisition	Negative
Celularity	Neutral

48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 19.0% of Celularity shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by insiders. Comparatively, 17.3% of Celularity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

JATT Acquisition has higher earnings, but lower revenue than Celularity.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Celularity	$26.55M	0.69	-$91.72M	-$3.33	N/A

Summary

JATT Acquisition and Celularity tied by winning 6 of the 12 factors compared between the two stocks.

How does Celularity compare to Rallybio?

Rallybio (NASDAQ:RLYB) and Celularity (NASDAQ:CELU) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

Celularity has a net margin of -345.45% compared to Rallybio's net margin of -911.07%. Celularity's return on equity of 0.00% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-55.79%	-51.48%
Celularity	-345.45%	N/A	-77.94%

Rallybio has higher earnings, but lower revenue than Celularity. Rallybio is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	98.17	-$8.98M	-$4.34	N/A
Celularity	$26.55M	0.69	-$91.72M	-$3.33	N/A

Celularity has a consensus target price of $6.00, indicating a potential upside of 844.44%. Given Celularity's stronger consensus rating and higher possible upside, analysts clearly believe Celularity is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Celularity	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Rallybio had 2 more articles in the media than Celularity. MarketBeat recorded 2 mentions for Rallybio and 0 mentions for Celularity. Rallybio's average media sentiment score of 0.95 beat Celularity's score of 0.00 indicating that Rallybio is being referred to more favorably in the media.

Company	Overall Sentiment
Rallybio	Positive
Celularity	Neutral

Rallybio has a beta of -0.9, indicating that its stock price is 190% less volatile than the broader market. Comparatively, Celularity has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

90.3% of Rallybio shares are held by institutional investors. Comparatively, 19.0% of Celularity shares are held by institutional investors. 10.3% of Rallybio shares are held by insiders. Comparatively, 17.3% of Celularity shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Celularity beats Rallybio on 10 of the 16 factors compared between the two stocks.

Get Celularity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELU vs. The Competition

Export

Metric	Celularity	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$18.39M	$3.55B	$7.16B	$12.47B
Dividend Yield	N/A	3.78%	2.59%	9.45%
P/E Ratio	-0.19	7.38	282.25	24.66
Price / Sales	0.69	1,254.29	583.24	88.77
Price / Cash	N/A	98.58	71.23	59.99
Price / Book	-0.48	16.80	11.09	5.90
Net Income	-$91.72M	-$12.46M	$3.50B	$336.31M
7 Day Performance	-15.29%	-1.47%	-0.24%	0.09%
1 Month Performance	2.52%	-8.45%	-3.70%	-5.17%
1 Year Performance	-79.64%	48.32%	61.98%	18.61%

Celularity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELU Celularity	1.6884 of 5 stars	$0.64 -6.6%	$6.00 +844.4%	-79.6%	$18.39M	$26.55M	N/A	220	Gap Up
AADI Aadi Bioscience	N/A	$3.79 -2.6%	N/A	+120.0%	$93.60M	$25.07M	N/A	40
VRCA Verrica Pharmaceuticals	2.1874 of 5 stars	$5.44 -0.9%	$14.50 +166.5%	-7.4%	$93.46M	$35.58M	N/A	40	News Coverage Upcoming Earnings
HRTX Heron Therapeutics	1.8646 of 5 stars	$0.48 -0.7%	$2.50 +423.9%	-70.8%	$90.32M	$154.90M	N/A	300	Positive News
JATT JATT Acquisition	N/A	$11.22 +2.0%	N/A	+761.4%	$90.04M	N/A	N/A	3	Negative News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELU) was last updated on 8/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celularity (CELU) Competitors

CELU vs. AADI, VRCA, HRTX, JATT, and RLYB

How does Celularity compare to Aadi Bioscience?

Summary

How does Celularity compare to Verrica Pharmaceuticals?

Summary

How does Celularity compare to Heron Therapeutics?

Summary

How does Celularity compare to JATT Acquisition?

Summary

How does Celularity compare to Rallybio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celularity (CELU) Competitors

CELU vs. AADI, VRCA, HRTX, JATT, and RLYB

How does Celularity compare to Aadi Bioscience?

Is AADI or CELU more profitable?

Which has higher valuation & earnings, AADI or CELU?

Which has more risk and volatility, AADI or CELU?

Does the media favor AADI or CELU?

Do analysts prefer AADI or CELU?

Do insiders & institutionals have more ownership in AADI or CELU?

Summary

How does Celularity compare to Verrica Pharmaceuticals?

Do analysts rate CELU or VRCA?

Does the media prefer CELU or VRCA?

Which has more risk & volatility, CELU or VRCA?

Is CELU or VRCA more profitable?

Do institutionals & insiders hold more shares of CELU or VRCA?

Which has higher earnings & valuation, CELU or VRCA?

Summary

How does Celularity compare to Heron Therapeutics?

Which has more volatility & risk, HRTX or CELU?

Do insiders & institutionals hold more shares of HRTX or CELU?

Is HRTX or CELU more profitable?

Which has stronger valuation & earnings, HRTX or CELU?

Does the media prefer HRTX or CELU?

Do analysts rate HRTX or CELU?

Summary

How does Celularity compare to JATT Acquisition?

Is JATT or CELU more profitable?

Do analysts prefer JATT or CELU?

Does the media prefer JATT or CELU?

Do institutionals and insiders believe in JATT or CELU?

Which has better earnings & valuation, JATT or CELU?

Summary

How does Celularity compare to Rallybio?

Is RLYB or CELU more profitable?

Which has preferable valuation and earnings, RLYB or CELU?

Do analysts rate RLYB or CELU?

Does the media favor RLYB or CELU?

Which has more risk and volatility, RLYB or CELU?

Do insiders and institutionals believe in RLYB or CELU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELU vs. The Competition

Celularity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools